Atrophic acne scar Atrophic acne scar
Conditions
Interventions
operative care
Before treatment,
all treatment areas were gently cleansed with mild cleanser. Then,
local anesthetic cream ,
lidocaine 2.5% and prilocaine 2.5% cream(Rascer®,
Galentic Pharma,
India),
was applied under occlusion 45 minutes prior to
procedure.
Intervention
Each participant’s entire face was treated with an ablative fractional CO2 laser (Smartxide Touch Fractionated CO2 Laser,
Italy). After fractional
CO2 laser,
facial halves were randomly assigned to receive treatment with topical epidermal growth factor (Epidermal growth factor,
Siam Bioscience Co.,
Thailand ) on one side and fragrance-
free,
noncomedogenic moisturizer as a placebo on the other side with full-
face occlusion for 30 minutes. Air cooling and ice packs were used to minimize pain during and after the procedure. Then,
participants were
discharged after removing the occlusion without cleansing of the topical creams.
Post-
operative care
After treatment,
Sponsors
Thammasat University
Assistant Professor Punyaphat Sirithanabadeekul,
M.D.
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Healthy males and females between 18 to 50 years old. 2. Fitzpatrick skin Types III to V 3. Patients who have Goodman and Baron grading II-IV atrophic acne scars
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating woman. 2. Patients who have a history of keloid or hypertrophic scar formation. 3. Patients who have active facial acne or any active facial inflammation. 4. Patients who had been taking oral isotretinoin within the preceding 6 months. 5. Patients who had been taking ablative laser within the preceding 6 months. 6. Patients who had been taking nonablative laser within the preceding 3 months. 7. Patients who have diabetes mellitus. 8. Patients who have collagen vascular disease. 9. Patients who have history of skin cancer. 10. Patients who have history of herpes labialis. 11. Patients who have allergic history to topical EGF or ingredients of placebo. 12. Patients who have allergic history to topical anesthetic cream.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| scar improvement using Quartile grading scale At 1 month and 3 months after the final treatment session by two blinded dermatologists | — |
Secondary
| Measure | Time frame |
|---|---|
| scar improvement by Antera 3D® camera At 1 month and 3 months after the final treatment session Antera 3D® skin analysis camera system, Post-procedure wound healing response assess daily for 7 days after the treatment session Erythema grading and scab shedding by physical investigator,Side effect evaluation (Erythema, edema and other side effects including petechiae, oozing, crustin) At Day 7, month 1, month 2, month 3 and month 5 physical investigator , Antera 3D®,Patient’s satisfaction evaluation At month 1, month 2, month 3 and month 5 Visual analogue scale (0-10) | — |
Countries
Thailand
Contacts
Public ContactYanisa Ratanapokasatit
Department of Dermatology, Chulabhorn International College of Medicine, Thammasat university
Outcome results
None listed